Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors

REFERENCES

• Agapova, L. S., J. L. Volodina, P. M. Chumakov, and B. P. Kopnin. 2004. Activation of Ras-Ral pathway attenuates p53-independent DNA damage G2 checkpoint. J. Biol. Chem. 279:36382–36389.
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso, J. A., P. Frankel, E. F. Farias, Z. Lu, H. Jiang, A. Olsen, L. A. Feig, E. B. de Kier Joffe, and D. A. Foster. 1999. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene 18:4718–4725.
   PubMedGoogle Scholar
• Bajenaru, M. L., J. Donahoe, T. Corral, K. M. Reilly, S. Brophy, A. Pellicer, and D. H. Gutmann. 2001. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33:314–323.
   PubMedGoogle Scholar
• Bajenaru, M. L., M. R. Hernandez, A. Perry, Y. Zhu, L. F. Parada, J. R. Garbow, and D. H. Gutmann. 2003. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 63:8573–8577.
   PubMed Web of Science ®Google Scholar
• Baum, B., J. Settleman, and M. P. Quinlan. 2008. Transitions between epithelial and mesenchymal states in development and disease. Semin. Cell Dev. Biol. 19:294–308.
   PubMed Web of Science ®Google Scholar
• Bernot, D., A. M. Benoliel, F. Peiretti, S. Lopez, B. Bonardo, P. Bongrand, I. Juhan-Vague, and G. Nalbone. 2003. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J. Cardiovasc. Pharmacol. 41:316–324.
   PubMedGoogle Scholar
• Bodemann, B. O., and M. A. White. 2008. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat. Rev. Cancer 8:133–140.
   PubMed Web of Science ®Google Scholar
• Bollag, G., S. Freeman, J. F. Lyons, and L. E. Post. 2003. Raf pathway inhibitors in oncology. Curr. Opin. Investig. Drugs 4:1436–1441.
   PubMedGoogle Scholar
• Brannan, C. I., A. S. Perkins, K. S. Vogel, N. Ratner, M. L. Nordlund, S. W. Reid, A. M. Buchberg, N. A. Jenkins, L. F. Parada, and N. G. Copeland. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:1019–1029.
   PubMed Web of Science ®Google Scholar
• Campbell, P. M., and C. J. Der. 2004. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 14:105–114.
   PubMed Web of Science ®Google Scholar
• Cantor, S. B., T. Urano, and L. A. Feig. 1995. Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol. Cell. Biol. 15:4578–4584.
   PubMed Web of Science ®Google Scholar
• Chien, Y., and M. A. White. 2003. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep. 4:800–806.
   PubMed Web of Science ®Google Scholar
• Cichowski, K., and T. Jacks. 2001. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604.
   PubMed Web of Science ®Google Scholar
• Cichowski, K., T. S. Shih, E. Schmitt, S. Santiago, K. Reilly, M. E. McLaughlin, R. T. Bronson, and T. Jacks. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science 286:2172–2176.
   PubMed Web of Science ®Google Scholar
• Corral, T., M. Jimenez, I. Hernandez-Munoz, I. Perez de Castro, and A. Pellicer. 2003. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J. Cell Physiol. 197:214–224.
   PubMedGoogle Scholar
• Courtois-Cox, S., S. M. Genther Williams, E. E. Reczek, B. W. Johnson, L. T. McGillicuddy, C. M. Johannessen, P. E. Hollstein, M. MacCollin, and K. Cichowski. 2006. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459–472.
   PubMed Web of Science ®Google Scholar
• Cox, A. D., and C. J. Der. 2002. Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 1:599–606.
   PubMed Web of Science ®Google Scholar
• Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11–22.
   PubMed Web of Science ®Google Scholar
• Feig, L. A. 2003. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol. 13:419–425.
   PubMed Web of Science ®Google Scholar
• Feldkamp, M. M., L. Angelov, and A. Guha. 1999. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg. Neurol. 51:211–218.
   PubMedGoogle Scholar
• Ferner, R. E. 2007. Neurofibromatosis 1. Eur. J. Hum. Genet. 15:131–138.
   PubMed Web of Science ®Google Scholar
• Frahm, S., A. Kurtz, L. Kluwe, F. Farassati, R. E. Friedrich, and V. F. Mautner. 2004. Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. Cancer Cell Int. 4:4.
   PubMedGoogle Scholar
• Frankel, P., A. Aronheim, E. Kavanagh, M. S. Balda, K. Matter, T. D. Bunney, and C. J. Marshall. 2005. RalA interacts with ZONAB in a cell density-dependent manner and regulates its transcriptional activity. EMBO J. 24:54–62.
   PubMed Web of Science ®Google Scholar
• Giehl, K. 2005. Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386:193–205.
   PubMed Web of Science ®Google Scholar
• Goldfinger, L. E. 2008. Choose your own path: specificity in Ras GTPase signaling. Mol. Biosyst. 4:293–299.
   PubMedGoogle Scholar
• Guarino, M., B. Rubino, and G. Ballabio. 2007. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305–318.
   PubMed Web of Science ®Google Scholar
• Gutmann, D. H. 2001. The neurofibromatoses: when less is more. Hum. Mol. Genet. 10:747–755.
   PubMed Web of Science ®Google Scholar
• Hamad, N. M., J. H. Elconin, A. E. Karnoub, W. Bai, J. N. Rich, R. T. Abraham, C. J. Der, and C. M. Counter. 2002. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2045–2057.
   PubMed Web of Science ®Google Scholar
• Harrisingh, M. C., and A. C. Lloyd. 2004. Ras/Raf/ERK signalling and NF1. Cell Cycle 3:1255–1258.
   PubMed Web of Science ®Google Scholar
• Harrisingh, M. C., E. Perez-Nadales, D. B. Parkinson, D. S. Malcolm, A. W. Mudge, and A. C. Lloyd. 2004. The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J. 23:3061–3071.
   PubMed Web of Science ®Google Scholar
• Hugo, H., M. L. Ackland, T. Blick, M. G. Lawrence, J. A. Clements, E. D. Williams, and E. W. Thompson. 2007. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell Physiol. 213:374–383.
   PubMed Web of Science ®Google Scholar
• Jones, H. A., S. M. Hahn, E. Bernhard, and W. G. McKenna. 2001. Ras inhibitors and radiation therapy. Semin. Radiat. Oncol. 11:328–337.
   PubMed Web of Science ®Google Scholar
• Jullien-Flores, V., O. Dorseuil, F. Romero, F. Letourneur, S. Saragosti, R. Berger, A. Tavitian, G. Gacon, and J. H. Camonis. 1995. Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J. Biol. Chem. 270:22473–22477.
   PubMed Web of Science ®Google Scholar
• Lakkis, M. M., and G. I. Tennekoon. 2000. Neurofibromatosis type 1. I. General overview. J. Neurosci. Res. 62:755–763.
   PubMed Web of Science ®Google Scholar
• Legius, E., H. Dierick, R. Wu, B. K. Hall, P. Marynen, J. J. Cassiman, and T. W. Glover. 1994. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10:250–255.
   PubMed Web of Science ®Google Scholar
• Lim, K. H., A. T. Baines, J. J. Fiordalisi, M. Shipitsin, L. A. Feig, A. D. Cox, C. J. Der, and C. M. Counter. 2005. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7:533–545.
   PubMed Web of Science ®Google Scholar
• Lim, K. H., K. O'Hayer, S. J. Adam, S. D. Kendall, P. M. Campbell, C. J. Der, and C. M. Counter. 2006. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 16:2385–2394.
   PubMed Web of Science ®Google Scholar
• Ling, B. C., J. Wu, S. J. Miller, K. R. Monk, R. Shamekh, T. A. Rizvi, G. Decourten-Myers, K. S. Vogel, J. E. DeClue, and N. Ratner. 2005. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7:65–75.
   PubMed Web of Science ®Google Scholar
• Lothe, R. A., B. Smith-Sorensen, M. Hektoen, A. E. Stenwig, N. Mandahl, G. Saeter, and F. Mertens. 2001. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 30:202–206.
   PubMedGoogle Scholar
• Lu, Z., A. Hornia, T. Joseph, T. Sukezane, P. Frankel, M. Zhong, S. Bychenok, L. Xu, L. A. Feig, and D. A. Foster. 2000. Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts. Mol. Cell. Biol. 20:462–467.
   PubMedGoogle Scholar
• Lundquist, E. A. 2006. Small GTPases. WormBook doi:10.1895/wormbook.1.67.1. www.wormbook.org .
   PubMedGoogle Scholar
• Lynch, T. M., and D. H. Gutmann. 2002. Neurofibromatosis 1. Neurol. Clin. 20:841–865.
   PubMedGoogle Scholar
• Malumbres, M., I. Perez De Castro, M. I. Hernandez, M. Jimenez, T. Corral, and A. Pellicer. 2000. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15INK4b. Mol. Cell. Biol. 20:2915–2925.
   PubMedGoogle Scholar
• Martello, L. A., and A. Pellicer. 2005. Biochemical and biological analyses of Rgr RalGEF oncogene. Methods Enzymol. 407:115–128.
   Google Scholar
• Mashour, G. A., S. N. Drissel, S. Frahm, F. Farassati, R. L. Martuza, V. F. Mautner, A. Kindler-Rohrborn, and A. Kurtz. 2005. Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. Oncogene 24:2367–2374.
   PubMedGoogle Scholar
• McCormick, F. 1995. Ras signaling and NF1. Curr. Opin. Genet. Dev. 5:51–55.
   PubMedGoogle Scholar
• Menon, A. G., K. M. Anderson, V. M. Riccardi, R. Y. Chung, J. M. Whaley, D. W. Yandell, G. E. Farmer, R. N. Freiman, J. K. Lee, and F. P. Li. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87:5435–5439.
   PubMed Web of Science ®Google Scholar
• Moskalenko, S., D. O. Henry, C. Rosse, G. Mirey, J. H. Camonis, and M. A. White. 2002. The exocyst is a Ral effector complex. Nat. Cell Biol. 4:66–72.
   PubMed Web of Science ®Google Scholar
• Mousley, C. J., K. R. Tyeryar, M. M. Ryan, and V. A. Bankaitis. 2006. Sec14p-like proteins regulate phosphoinositide homoeostasis and intracellular protein and lipid trafficking in yeast. Biochem. Soc. Trans. 34:346–350.
   PubMedGoogle Scholar
• Oxford, G., C. R. Owens, B. J. Titus, T. L. Foreman, M. C. Herlevsen, S. C. Smith, and D. Theodorescu. 2005. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res. 65:7111–7120.
   PubMedGoogle Scholar
• Polette, M., M. Mestdagt, S. Bindels, B. Nawrocki-Raby, W. Hunziker, J. M. Foidart, P. Birembaut, and C. Gilles. 2007. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 185:61–65.
   PubMed Web of Science ®Google Scholar
• Rajalingam, K., R. Schreck, U. R. Rapp, and S. Albert. 2007. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773:1177–1195.
   PubMed Web of Science ®Google Scholar
• Rasmussen, S. A., and J. M. Friedman. 2000. NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 151:33–40.
   PubMed Web of Science ®Google Scholar
• Rey, J. A., A. Pestana, and M. J. Bello. 1992. Cytogenetics and molecular genetics of nervous system tumors. Oncol. Res. 4:321–331.
   PubMedGoogle Scholar
• Sablina, A. A., W. Chen, J. D. Arroyo, L. Corral, M. Hector, S. E. Bulmer, J. A. DeCaprio, and W. C. Hahn. 2007. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell 129:969–982.
   PubMed Web of Science ®Google Scholar
• Serra, E., S. Puig, D. Otero, A. Gaona, H. Kruyer, E. Ars, X. Estivill, and C. Lazaro. 1997. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am. J. Hum. Genet. 61:512–519.
   PubMed Web of Science ®Google Scholar
• Sherman, L. S., R. Atit, T. Rosenbaum, A. D. Cox, and N. Ratner. 2000. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 275:30740–30745.
   PubMed Web of Science ®Google Scholar
• Sugihara, K., S. Asano, K. Tanaka, A. Iwamatsu, K. Okawa, and Y. Ohta. 2002. The exocyst complex binds the small GTPase RalA to mediate filopodia formation. Nat. Cell Biol. 4:73–78.
   PubMed Web of Science ®Google Scholar
• Thomas, S. L., G. D. Deadwyler, J. Tang, E. B. Stubbs, Jr., D. Muir, K. K. Hiatt, D. W. Clapp, and G. H. De Vries. 2006. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. Biochem. Biophys. Res. Commun. 348:971–980.
   PubMedGoogle Scholar
• Tong, J., F. Hannan, Y. Zhu, A. Bernards, and Y. Zhong. 2002. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5:95–96.
   PubMedGoogle Scholar
• Tong, T., Y. Zhong, J. Kong, L. Dong, Y. Song, M. Fu, Z. Liu, M. Wang, L. Guo, S. Lu, M. Wu, and Q. Zhan. 2004. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin. Cancer Res. 10:7304–7310.
   PubMed Web of Science ®Google Scholar
• Trovo-Marqui, A. B., and E. H. Tajara. 2006. Neurofibromin: a general outlook. Clin. Genet. 70:1–13.
   PubMed Web of Science ®Google Scholar
• Tse, J. C., and R. Kalluri. 2007. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell Biochem. 101:816–829.
   PubMed Web of Science ®Google Scholar
• Turley, E. A., M. Veiseh, D. C. Radisky, and M. J. Bissell. 2008. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5:280–290.
   PubMedGoogle Scholar
• Upadhyaya, M., G. Spurlock, E. Majounie, S. Griffiths, N. Forrester, M. Baser, S. M. Huson, D. G. Evans, and R. Ferner. 2006. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum. Mutat. 27:716.
   PubMed Web of Science ®Google Scholar
• van Dam, E. M., and P. J. Robinson. 2006. Ral: mediator of membrane trafficking. Int. J. Biochem. Cell Biol. 38:1841–1847.
   PubMed Web of Science ®Google Scholar
• Vasudevan, A., Y. Qian, A. Vogt, M. A. Blaskovich, J. Ohkanda, S. M. Sebti, and A. D. Hamilton. 1999. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J. Med. Chem. 42:1333–1340.
   PubMedGoogle Scholar
• Vogel, K. S., L. J. Klesse, S. Velasco-Miguel, K. Meyers, E. J. Rushing, and L. F. Parada. 1999. Mouse tumor model for neurofibromatosis type 1. Science 286:2176–2179.
   PubMed Web of Science ®Google Scholar
• Weiss, B., G. Bollag, and K. Shannon. 1999. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89:14–22.
   PubMed Web of Science ®Google Scholar
• Yamamoto, T., S. Taya, and K. Kaibuchi. 1999. Ras-induced transformation and signaling pathway. J. Biochem. 126:799–803.
   PubMedGoogle Scholar
• Yin, J., C. Pollock, K. Tracy, M. Chock, P. Martin, M. Oberst, and K. Kelly. 2007. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol. Cell. Biol. 27:7538–7550.
   PubMedGoogle Scholar
• Zohn, I. E., Y. Li, E. Y. Skolnik, K. V. Anderson, J. Han, and L. Niswander. 2006. p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 125:957–969.
   PubMed Web of Science ®Google Scholar